Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience
Objectives: This study aimed to compare the effectiveness of nivolumab and axitinib as second-line treatments in patients with metastatic renal cell carcinoma (mRCC) who had progressed after one prior tyrosine kinase inhibitor (TKI)-based therapy. Methods: We retrospectively evaluated 68 patients with mRCC who received...